Veozah evaluation for menopause symptoms in NYC

Veozah is a nonhormonal daily prescription option for moderate to severe hot flashes and night sweats due to menopause. Evaluation includes symptom fit, medication interactions, kidney and liver history, baseline liver tests, and a follow-up testing plan.

Quick answer

Veozah is a nonhormonal daily prescription option for moderate to severe hot flashes and night sweats due to menopause. Evaluation includes symptom fit, medication interactions, kidney and liver history, baseline liver tests, and a follow-up testing plan.

Eligibility and care boundaries

The visit begins with the clinical question and the records that can change the next step.

Symptoms and bleeding

Review hot flashes, night sweats, sleep impact, the menopause timeline, and any unexpected or postmenopausal bleeding.

Liver and kidney boundaries

Known cirrhosis, severe renal impairment, and end-stage renal disease are important label limits.

Complete medication list

Prescription medicines, over-the-counter products, and supplements must be checked for CYP1A2 inhibition and other concerns.

Monitoring commitment

The current label calls for liver tests before treatment, monthly for the first three months, and again at months six and nine.

How care works

Evaluate the symptom pattern

A clinician confirms that moderate to severe vasomotor symptoms are the treatment target and checks for bleeding or another condition that needs separate care.

Review medicines and laboratory needs

The visit covers liver and kidney history, interacting medicines, baseline hepatic tests, and the ability to complete follow-up monitoring.

Coordinate prescription access

If Veozah is appropriate, the care team can address the prescription, coverage review, and follow-up timing. Dispensing and coverage are not guaranteed.

Monitor response and safety

Follow-up checks symptom response, adverse effects, liver-test completion, new medicines, and symptoms that require stopping treatment.

Veozah treats vasomotor symptoms, not every menopause concern

Veozah is FDA approved for moderate to severe vasomotor symptoms due to menopause. It does not treat unexplained bleeding, vaginal symptoms, urinary symptoms, osteoporosis, or every cause of sleep or mood change.

A broader menopause evaluation can compare Veozah with Lynkuet, hormone therapy, other nonhormonal medicines, and non-drug approaches. Treatment choice depends on the symptom target and individual risk profile.

Unexpected bleeding, a new breast concern, severe pelvic pain, or symptoms outside a typical menopause pattern need their own evaluation rather than being attributed to hot flashes.

Stop Veozah and seek prompt medical care for possible liver injury

The current boxed warning directs patients to stop Veozah and seek medical attention for new fatigue, poor appetite, nausea, vomiting, itching, yellow skin or eyes, pale stool, dark urine, or abdominal pain. Call 911 for a severe allergic reaction or another medical emergency.

Insurance and access

Coverage may depend on formulary status, diagnosis, prior authorization, pharmacy, baseline results, and completion of the liver-monitoring plan. Staff can review access steps, but they cannot guarantee approval, dispensing, or out-of-pocket cost.

Clinics available for Veozah evaluation and coordination

The 11 clinic cards represent evaluation access only. Confirm an eligible clinic before the visit. They do not state that every clinic stocks medication, completes every laboratory workflow, or guarantees prescribing.